Tenax Therapeutics (NASDAQ:TENX) rose 11.35% on June 23, 2026, as pulmonary hypertension programme attracted biotech demand, with shares closing at $13.64.
Key Highlights
- Rose 11.35%: Tenax Therapeutics closed at $13.64 on June 23 after moving $1.39 per share.
- Catalyst: During the session, pulmonary hypertension programme attracted biotech demand.
- Company: Tenax Therapeutics develops treatments for pulmonary hypertension and related cardiovascular conditions.
- Session: The stock finished at $13.64, while the available company record showed a disclosed catalyst for the move.
Tenax Therapeutics (NASDAQ:TENX) rose 11.35% on June 23, 2026, closing at $13.64 after a $1.39 per-share move. The session’s advance came as pulmonary hypertension programme attracted biotech demand, based on the available company disclosures and trading context.
Continued enthusiasm around levosimendan as a potential therapy for pulmonary arterial hypertension, combined with broader biotech momentum in the small-cap space, helped support the stock. Tenax is running clinical trials for levosimendan in pulmonary hypertension, a high-unmet-need condition where existing options are limited.
Tenax Therapeutics develops treatments for pulmonary hypertension and related cardiovascular conditions.
No additional trial data or FDA meeting outcome was disclosed during the session. Speculative positioning ahead of anticipated data added to the move.
The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.
The shares closed at $13.64 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.
For the June 23 close, the defining facts were the 11.35% advance, the $13.64 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...